Skip to main content
  • Careers
    • Who Are We?
    • More Than
    • Benefits
    • Job Opportunities
  • Social Media
Acceleron Company
  • About
    • Our company
    • Management
    • Board of directors
    • Partners
    • Contact us
  • Our medicines
    • Reblozyl®
  • Science
    • What is the TGF-Beta Superfamily?
    • Luspatercept
    • Sotatercept
    • ACE-1334
    • Publications
      • Luspatercept
      • Sotatercept
      • ACE-083
      • ACE-1332
  • Pipeline
  • Disease Education
    • Pulmonary
    • Hematology
  • Patients
    • Our Medicines
    • Clinical Trials
    • More Than Rare
    • Patient Resources
    • Professional Organizations
      & Advocacy
    • Expanded Access
  • Home
    • News
    • Events & Presentations
      • Archived Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Meeting
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Resources
      • ESG
      • Investor FAQs
      • Investor Email Alerts
      • Investor & Media Contacts

Pricing delayed by 20 minutes.

Committee Composition

  • About
    • Our company
    • Management
    • Board of directors
    • Partners
    • Contact us
  • Our medicines
    • Reblozyl®
  • Science
    • What is TGF-Beta Superfamily?
    • Luspatercept
    • Sotatercept
    • ACE-1334
    • Publications
      • Luspatercept
      • Sotatercept
      • ACE-083
      • ACE-1332
  • Pipeline
  • Disease Education
    • Pulmonary
    • Hematology
  • Patients
    • Our Medicines
    • Clinical Trials
    • More Than Rare
    • Patient Resources
    • Professional Organizations
      & Advocacy
    • Expanded Access
  • Careers
    • Who Are We?
    • More Than
    • Benefits
    • Job Opportunities
  • Investors & Media
  • Home
    • News
    • Events & Presentations
      • Archived Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Meeting
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Resources
      • ESG
      • Investor FAQs
      • Investor Email Alerts
      • Investor & Media Contacts
  • Home
    • News
    • Events & Presentations
      • Archived Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Meeting
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Resources
      • ESG
      • Investor FAQs
      • Investor Email Alerts
      • Investor & Media Contacts

Quick Links

  • ESG
  • SEC Filings
  • Investor FAQs
  • Quarterly Results
  • Events & Presentations

IR Contact

Jamie Bernard, IRC
Associate Director, Investor Relations
investor@acceleronpharma.com

Media Contact

Matt Fearer
Senior Director, Corporate Communications
mfearer@acceleronpharma.com


Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Acceleron Pharma Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Acceleron Pharma Inc. to send you the requested Investor Email Alert updates.

* Required

*
*




Unsubscribe

Email Alert Sign Up Confirmation

Acceleron Company

128 Sidney Street

Cambridge, MA 02139

Tel: (617) 649-9200

Contact us
Breakthrough Drug of the Year
Acceleron Pharma
©2021 Acceleron Pharma Inc. All Rights Reserved.
Powered By Q4 Inc. 5.66.0.1 (opens in new window)
  • Sitemap
  • Community Guidelines
  • Privacy Policy